Advances in knowledge regarding the pathogenesis of psoriasis have allowed the development of a new class of agents known as biologic drugs. Data confirm that T helper (Th)17 and interleukin (IL)-17 signaling has a crucial role in the pathogenesis of the disease. High levels of IL-17 and Th17-related cytokines have been reported in psoriasis, leading to the suggestion of agents targeting IL-17 as a potential therapeutic strategy in psoriasis. Brodalumab is a human monoclonal antibody that targets IL-17 receptor A, blocking the effects of IL-17A, IL-17F, and IL-17E. Data from Phase I and Phase II clinical trials indicate that brodalumab has a favorable safety and tolerability profile, with strong clinical activity, suggesting that it is a potential tool for use in the treatment of moderate-to-severe psoriasis. © 2014 Coimbra et al.
CITATION STYLE
Coimbra, S., Figueiredo, A., & Santos-Silva, A. (2014, July 21). Brodalumab: An evidence-based review of its potential in the treatment of moderate-to-severe psoriasis. Core Evidence. Dove Medical Press Ltd. https://doi.org/10.2147/CE.S33940
Mendeley helps you to discover research relevant for your work.